InflaRx NV, a clinical-stage biopharmaceutical company headquartered in Jena, Germany, operates within the health care sector, specifically focusing on biotechnology. The company is renowned for its specialization in the discovery and development of monoclonal antibody drugs aimed at treating inflammatory diseases. InflaRx NV serves a global patient base and is listed on the Frankfurt Stock Exchange, trading under the currency of the Euro (EUR).
As of December 28, 2025, InflaRx NV’s closing stock price was recorded at €0.9205. Over the past year, the company’s stock has experienced significant volatility, with a 52-week high of €2.60 on January 15, 2025, and a 52-week low of €0.623 on May 27, 2025. This fluctuation reflects the dynamic nature of the biotechnology sector and the challenges faced by companies in this field.
The market capitalization of InflaRx NV stands at €64,523,712, indicating the total market value of its outstanding shares. Despite its innovative focus, the company’s financial performance has been marked by a negative price-to-earnings (P/E) ratio of -1.66, suggesting that it is currently not generating profits. However, the price-to-book (P/B) ratio of 1.45 indicates that the stock is trading above its book value, which may reflect investor confidence in the company’s long-term potential.
A significant development for InflaRx NV occurred on December 11, 2025, when it announced that its product INF904 had been assigned the international non-proprietary name “Izicopan.” This milestone is crucial for the company’s pipeline, as it progresses towards regulatory approval and commercialization. However, since this announcement, InflaRx NV has not issued any further updates, leaving investors and stakeholders anticipating future developments.
InflaRx NV was initially public through an Initial Public Offering (IPO) on November 8, 2017. Since then, the company has focused on advancing its therapeutic candidates, with Izicopan being a key asset in its portfolio. The company’s website, www.inflarx.de , provides additional information and resources for those interested in its ongoing research and development efforts.
In summary, InflaRx NV remains a notable player in the biotechnology sector, with a focus on innovative treatments for inflammatory diseases. Despite current financial challenges, the company’s strategic developments, such as the naming of Izicopan, highlight its potential for future growth and success in the healthcare industry.
